TIANJIN, China, Dec. 27 /Xinhua-PRNewswire/ -- Asymchem, one of China's leading CMO companies, announced today the Company's investment and expansion plans in China. Apart from new plants and R & D facility, the Company will also invest heavily in training and form strategic alliances in the near future.
I. Quality Facilities: New cGMP Pilot Plant and R&D Building became Operational in October, 2007
The new Asymchem Life Science (Tianjin) Co., Ltd site began operation with the opening of its new cGMP Pilot Plant in October 2007 and projected opening of a new R&D Building 1Q 2008. The initial investment for the site to date is 180 million RMB, with further construction on-going for completion in late 2008.
A total investment of 480 million RMB has been allotted for the 100,000 sqm site located in TEDA, Tianjin, one of the more prestigious high tech parks in China. Asymchem will build cGMP production facilities following ICH Q7A guidelines. Supporting facilities at this site will include an R&D center, an analytical research center and an EHS center that follow international standards. The goal is to achieve comprehensive facilities for development and production of cGMP intermediates and APIs at kilogram to mton scale. In the end, Asymchem will be in position to provide a variety of advanced technical services for pharmaceutical and biotech companies.
Phase I construction of Asymchem Life Science aims to build 12 separate
cGMP production modules in a 50,000 sqm facility. Following ICH Q7A
guidelines, these production modules with a total output of approximately
20mt of cGMP intermediate and APIs each year are designed according to
international concepts and are equipped with advanced HVAQ systems. So far,
many intermediates and API's of high value have been manufactured in this
Copyright©2007 PR Newswire.
All rights reserved